An FAH Carrier Result for Tyrosinemia Type I: What the Research Actually Says

An FAH Carrier Result for Tyrosinemia Type I: What the Research Actually Says

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: A home DNA report that flags one changed copy of the FAH gene describes a carrier, not a patient. GeneReviews says plainly that heterozygotes, meaning people with one altered copy, “are asymptomatic and are not at risk of developing the disorder” — that is, they have no symptoms. Every liver-failure and liver-cancer number in the research describes children with two pathogenic FAH variants. What a carrier result does raise are questions about a future child, and those have clear answers with numbers.

What you’ll learn

• Why one working copy of FAH is enough, and what the toxin succinylacetone does when both copies fail
• The odds for each pregnancy when one parent carries a variant, and when both do
• What a home carrier test can and cannot rule out, and how to get a clinic-grade test
• What newborn screening catches, and the dated FDA and Health Canada record for nitisinone

What tyrosinemia type I is: one blocked step and a toxin called succinylacetone

Tyrosine is an amino acid found in ordinary food protein. The body breaks it down in a series of steps, mostly in the liver and the kidney. The FAH gene holds the recipe for the enzyme that does the last step, called fumarylacetoacetate hydrolase. An enzyme is just a protein that speeds up one chemical reaction.

Picture the pathway as a five-station assembly line. When the last station shuts down, half-finished parts pile up behind it. That is the whole disease in one image. MedlinePlus Genetics puts it directly. When the enzyme is missing, fumarylacetoacetate and the steps before it build up and turn into succinylacetone, which harms liver and kidney cells.

Succinylacetone is the key compound in this article. It shows up only when FAH activity is low, which is why it later becomes both the newborn-screening marker and the test fingerprint. In children with two non-working copies of FAH, severe liver disease follows when no one treats it. GeneReviews states that untreated survivors of acute liver failure are at high risk of hepatocellular carcinoma, a liver cancer. Starting nitisinone early rather than late has also been linked to fewer kidney problems and fewer nerve crises in affected children.

Three points matter before going further.

• This is not caused by eating too much protein, and a normal diet does not cause it.
• It is not the same as tyrosinemia type II or type III. Those involve other enzymes, and MedlinePlus says liver problems do not happen in types II and III. Type II is rarer still: fewer than 1 in 250,000 people worldwide.
• A raised tyrosine level in a newborn is often harmless. About 1 in 10 newborns show a brief, non-genetic rise, usually from low vitamin C or a young liver.

Now the sentence a carrier came here for. A person with one working copy of FAH still makes working enzyme. Succinylacetone does not build up, and MedlinePlus says parents who each carry one copy “typically do not show signs and symptoms”. Nothing in the history above describes a carrier. If a report still leaves doubt, a family doctor can set up a genetics referral to confirm what the result means.

Section recap: Losing the last enzyme in tyrosine breakdown lets the toxin succinylacetone build up in liver and kidney cells. That takes two non-working copies, so it does not describe a carrier.

Autosomal recessive inheritance: why a carrier stays healthy, and the math that applies

Tyrosinemia type I is inherited in an autosomal recessive pattern, meaning both copies of the FAH gene must carry a pathogenic (disease-causing) variant before the condition appears. Everyone gets two copies of FAH, one from each birth parent. A carrier has one altered copy and one working copy.

GeneReviews puts the reassurance in one verified sentence: “Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder”. That sentence is doing a lot of work, so it is worth restating. A carrier is not a mild case, an early case, or a case waiting to happen.

The math that does apply is about children. GeneReviews sets it out for the brothers and sisters of an affected child, where both parents are carriers.

Each pregnancy, when both parents carry an FAH variant	Chance	Out of 100 pregnancies
Child affected (two pathogenic FAH variants)	25%	about 25
Child is a healthy carrier (one variant)	50%	about 50
Child carries neither variant	25%	about 25

Figures as published by GeneReviews for that specific couple.

Two rules that shorter pages skip are worth stating out loud.

Rule 1: the genes must match. A 25% figure applies only when both birth parents carry a pathogenic variant in FAH itself. A partner who carries a variant in some other metabolic gene does not create that risk here. Recessive risk is gene by gene, like two keys that must fit the same lock.

Rule 2: one carrier parent is not enough. If only one birth parent carries a pathogenic FAH variant, no child of that couple can have tyrosinemia type I. Each child instead has about a 50% chance of being a healthy carrier, just like the parent. This follows straight from the recessive pattern MedlinePlus describes.

Two more points stop common errors. The odds reset at every pregnancy, because each conception stands on its own, so a healthy first child changes nothing about the next one. And carrier status is nobody’s fault: GeneReviews notes that the parents of an affected child are simply presumed to each carry one altered copy.

For the reader’s own relatives, GeneReviews gives the cascade numbers too. Each brother or sister of a carrier’s parent has a 50% chance of being a carrier. The same logic makes each full sibling of a known carrier about 50% likely to carry it. A genetic counselor is a trained health worker who explains gene test results to families. One can walk a family through those numbers before anyone books a test. A doctor can do the same.

Section recap: One altered FAH copy makes a healthy carrier, and no child can be affected unless both birth parents carry a pathogenic FAH variant. When both do, each pregnancy carries about 25 chances in 100.

How common is it, and does French-Canadian, Finnish, or Norwegian ancestry change the odds

Two trusted sources describe how common tyrosinemia type I is, and they word it differently. They are quoted apart here on purpose. Averaging published figures would invent a number that no source backs.

Population	Reported rate	Source
Worldwide	about 1 in 100,000 people	MedlinePlus Genetics
Norway	1 in 60,000 to 74,000 people	MedlinePlus Genetics
Quebec, Canada	about 1 in 16,000 people	MedlinePlus Genetics
Saguenay-Lac-Saint-Jean, Quebec	1 in 1,846 people	MedlinePlus Genetics
Areas without newborn screening	about 1 in 90,000 to 120,000 births	GeneReviews
Finland	about 1 in 60,000 births	GeneReviews
Norway	about 1 in 74,800 births	GeneReviews
Quebec, Canada	about 1 in 16,000	GeneReviews
Saguenay-Lac-Saint-Jean, Quebec	1 in 1,846 live births	GeneReviews

Each row is quoted from one source only, and the rows are not blended.

Carrier frequency is the number that matters most to someone planning a pregnancy. GeneReviews puts the general United States carrier frequency at 1 in 100 to 1 in 150. Put simply, that is roughly 1 person or fewer in every 100. Newborn-screening data put the Quebec-wide carrier rate at about 1 in 66, and the Saguenay-Lac-Saint-Jean rate at 1 in 16 to 1 in 20. A rate of 1 in 16 means about 6 people in every 100.

The reason is a founder effect. When a small group settles a region and most marriages stay within it, one inherited variant gets concentrated over the years. It is less like a new change spreading and more like one card shuffled back into a small deck again and again.

GeneReviews names the variants in its variant table. The splice variant c.1062+5G>A, also written IVS12+5G>A, is the French-Canadian and Norwegian founder variant. The same table states that it “accounts for 87% of pathogenic variants in this population”. The Finnish founder variant is c.786G>A (p.Trp262Ter), and c.782C>T (p.Pro261Leu) is listed as an Ashkenazi Jewish founder variant. The first report of a single FAH mutation in French Canadians with this disease ran in the New England Journal of Medicine in 1994.

The upshot is narrow. Two partners who both trace their roots to the same founder region have a much higher chance of carrying the same variant. That is a reason to ask a doctor about testing the partner, not a reason to assume an outcome.

Section recap: Rates run near 1 in 100,000 worldwide, but founder regions differ sharply, down to 1 in 1,846 births in Saguenay-Lac-Saint-Jean. Ancestry sets the starting odds; it does not set the answer.

What a home carrier report tests, and what “variant not detected” does not rule out

This is where readers are most often misled, and the problem is coverage rather than accuracy.

23andMe’s own product page says its Tyrosinemia Type I carrier status report tests four variants in the FAH gene. The company describes the report as most relevant for people of French-Canadian and Finnish descent. It also says carrier status reports “cannot determine if you have two copies of any genetic variant”. They are likewise “not intended to tell you anything about your risk for developing a disease in the future,” or about the health of a fetus. That is company text about a company product. It is used here only to say what the product claims about itself.

Compare that with clinic-grade testing. The NIH Genetic Testing Registry lists clinical labs registered for tyrosinemia type I, including full FAH sequence analysis and deletion or duplication analysis. GeneReviews describes the same order from the clinic side. Testing starts with a targeted look at c.782C>T in Ashkenazi Jewish ancestry, or at c.1062+5G>A in French-Canadian ancestry. If nothing turns up, it moves to FAH sequencing, then to deletion and duplication analysis.

The point here is simple, and it needs no extra numbers. A targeted panel checks a fixed list of spots. By design it cannot find a variant that is not on the list. Think of a spell-checker with a short custom dictionary: it catches the words it knows and stays quiet on the rest.

So a partner result reading “variant not detected” lowers the risk that is left, sometimes by a lot, but it never drops that risk to zero. What is left is larger for people whose roots lie outside the founder groups. The panel was built around those groups in the first place.

Three kinds of result are worth knowing before any test is ordered.

• Carrier result. One pathogenic variant, in a person who is not affected and will not become affected.
• Variant of uncertain significance (VUS). A change whose meaning is not yet settled. It is not a carrier result, and it should not drive choices about having children.
• Negative screen. Risk drops, but it does not reach zero, because the panel only reads its own list.

Finally, a home result is a screen, not a diagnosis. The usual next step is a repeat test in a CLIA-certified US lab, where CLIA means the Clinical Laboratory Improvement Amendments, the federal quality standard for clinical labs. In Canada the equivalent is an accredited clinical lab. A family doctor or genetics clinic can order it.

Section recap: A four-variant home panel reads a fixed list and cannot see past it, so “variant not detected” means less risk, not none. FAH sequencing plus deletion and duplication analysis is the follow-up test.

Getting a real test in the US and Canada: who orders it, who pays, and where to start

Access to carrier testing looks very different on the two sides of the border, so this section splits by country.

In the United States, the American College of Medical Genetics and Genomics (ACMG) published a 2021 practice resource. It covers screening for autosomal recessive and X-linked conditions during pregnancy and before it. X-linked means the gene sits on the X chromosome, so the risk pattern differs between boys and girls. That resource moved US carrier screening away from testing only people with certain ancestry, and toward one panel offered to everyone who is pregnant or planning a pregnancy.

GeneReviews ties that guidance to this disease. It states that ACMG includes tyrosinemia type I among the disorders for which carrier screening “should be offered to all individuals who are pregnant or planning a pregnancy”. So a broad carrier panel ordered in routine US preconception care would be expected to include FAH.

Here is the route in each country, side by side.

Question	United States	Canada
Who orders it	Family doctor, OB or midwife, or a genetics clinic	Family doctor, OB or midwife, then referral to a provincial medical genetics program
What is offered	A broad carrier panel offered to everyone pregnant or planning a pregnancy	Panels are set province by province, so ask the local program
Who pays	Set plan by plan; ask the insurer and the lab for a written estimate first	Funding differs by province; broad panels are often paid out of pocket at a private lab
Certifying body for counselors	American Board of Genetic Counseling (ABGC)	Canadian Association of Genetic Counsellors (CAGC)
Where to start	The National Society of Genetic Counselors (NSGC) Find a Genetic Counselor directory	A provincial genetics clinic, or a CAGC-certified counselor

Payment is the part most pages skip. In the US, cover for broad carrier screening is set plan by plan. The honest instruction is to ask the insurer and the lab for a written estimate first. Labs publish self-pay prices that change often, so a current quote from the lab beats any figure remembered from an article.

In Canada, the route runs through the provincial system. A doctor refers the patient to a provincial medical genetics program, which orders the test. The Canadian Association of Genetic Counsellors (CAGC) is the national certifying body and association for counselors. Funding differs by province, and broad carrier panels are often paid out of pocket through private labs. The first call is a family doctor, an obstetrician or midwife, or a provincial genetics clinic.

GeneReviews gives the clinical reason for the one test that matters most here. It states that carrier testing should be considered for the reproductive partners of known carriers, “particularly if both partners are of the same ancestry”. So for a couple where one partner already has a carrier result, the highest-value single test is the other partner’s, not a repeat on the person who already knows.

GeneReviews also supports offering genetic counseling to young adults who are affected, are carriers, or are at risk of being carriers. Genetic counseling is a visit with that trained professional to go through what a result means, what testing is worth doing, and what the choices are. In the United States, counselors are certified by the American Board of Genetic Counseling (ABGC). The NSGC runs that directory. Booking that visit before a pregnancy, rather than during one, takes the time pressure out of every choice that follows.

Section recap: ACMG guidance supports offering carrier screening that includes tyrosinemia type I to everyone pregnant or planning a pregnancy. In Canada the route is a provincial genetics program on referral, so confirm cover and price in writing first.

Newborn screening: the safety net that rewrote this disease, and where it still has holes

For a couple who both carry a pathogenic FAH variant, newborn screening is the strongest reassurance on offer. It is also the part worth asking sharp questions about.

Tyrosinemia type I is a core condition on the US Recommended Uniform Screening Panel (RUSP), the list of conditions recommended for every newborn screening program. Canada has no federal version. Panels and markers are set province by province, so no single national Canadian statement is right, and parents need to ask their own provincial program what it measures.

The technical detail behind that question is the heart of this section. Succinylacetone builds up only when FAH activity is low, which makes it a near-perfect fingerprint for this disease. GeneReviews describes dried blood spots taken 24 to 72 hours after birth. Succinylacetone measured by tandem mass spectrometry is the first-tier test and “the most specific and sensitive marker”. Tyrosine, by contrast, is a second-tier test that “is neither a specific nor sensitive marker for this condition”.

The US and Canadian consensus group said the same thing plainly. Blood succinylacetone as the screening marker “is superior to observing tyrosine levels as a way of identifying neonates with HT-1”. HT-1 is the clinical short form for hereditary tyrosinemia type 1. That group of 11 US and Canadian practitioners also recorded strong agreement in favour of screening with succinylacetone, then confirming the diagnosis and treating early.

Four plain terms explain how well any screen works.

• Sensitivity: how often the test flags babies who really do have the condition.
• Specificity: how often it stays quiet for babies who do not.
• Positive predictive value (PPV): of the babies it flags, how many really have it.
• Negative predictive value (NPV): of the babies it clears, how many really are clear.

The measured accuracy is high. A systematic review in the Orphanet Journal of Rare Diseases found sensitivity and specificity both at 100% in case-control studies, covering 29 cases and 34,403 controls. In real screening programs, positive predictive values ran from 66.7% to 100%. The same authors were careful about the limit of that evidence: negative predictive values could not be worked out, because babies who screened negative were not followed up.

That limit has a published example. A 2023 report in the International Journal of Neonatal Screening described a nine-year-old boy with liver cancer in a scarred liver. Testing for the cause found tyrosinemia type 1. His newborn succinylacetone value nine years earlier had been 1.08 micromol/L against a cut-off of 1.20, so the screen read negative.

The authors put this down to milder variants making less succinylacetone. They note that the value also fell below cut-offs used elsewhere, which range from 1.29 to 10 micromol/L. As far as they know, it is the first published false negative from succinylacetone-based screening for this condition.

Read that as one recorded exception, not as proof that screening is unreliable. GeneReviews adds a related caveat: in the US, most newborn screening labs set their own cut-off levels, and these are not standardized nationwide. The useful move for parents-to-be is a short, direct question to the birth hospital or provincial program. Which marker does this program use, and what is the cut-off? A genetic counselor or paediatrician can help read the answer.

Section recap: Succinylacetone on dried blood spots is the accurate first-tier marker, and it beats tyrosine. One published false negative shows why asking which marker your program uses is fair.

Treatment today: nitisinone and a low-tyrosine diet, with the approval dates and the open questions

Nothing in this section describes the reader. Every figure below applies to children and adults with two pathogenic FAH variants, and a metabolic specialist manages the treatment.

The mechanism is one sentence. Nitisinone blocks an enzyme earlier in the tyrosine pathway, so the toxic later products and succinylacetone are never made. The trade-off is that tyrosine in the blood rises. That is why a low-tyrosine, low-phenylalanine diet with amino acid formula is part of the treatment rather than an optional extra.

Both countries keep a clear, dated record.

Regulator	Action	Date
US FDA	ORFADIN (nitisinone) capsules approved under NDA 021232	2002-01-18
Health Canada	Orfadin released through the Special Access Program for HT-1 patients	since 1994
Health Canada	Notice of Compliance issued to Swedish Orphan Biovitrum AB (publ) for Orfadin	2016-12-13
Health Canada	Notice of Compliance for Orfadin 4 mg/mL oral suspension	2017-11-14
Health Canada	MDK-Nitisinone, a second brand, marketed in Canada	since 2016

Drugs@FDA records ORFADIN as a new molecular entity that had priority review and orphan designation. Approved strengths on that application are 2 mg, 5 mg, 10 mg, and 20 mg oral capsules.

Canada’s path was different. Health Canada’s Summary Basis of Decision states that “Orfadin has been released through the Health Canada Special Access Program (SAP) for HT-1 patients since 1994”. Canadian patients could therefore get it long before market approval. The same record states that “On December 13, 2016, Health Canada issued a Notice of Compliance to Swedish Orphan Biovitrum AB (publ) for the drug product, Orfadin”. Health Canada’s Drug Product Database shows that MDK-Nitisinone has also been marketed in Canada since 2016, so more than one nitisinone product is now authorized there.

What doctors watch is published, and appears here only as background. GeneReviews lists nitisinone at 1.0 to 2.0 mg/kg/day, adjusted to keep blood nitisinone at 40 to 60 micromol/L. Diet targets are plasma tyrosine 300 to 600 micromol/L and plasma phenylalanine 20 to 80 micromol/L. Liver transplant is kept for severe liver failure that does not respond to nitisinone, or for cancer. None of these numbers is a self-care instruction.

The outcome shift is why this disease is described as rewritten within one lifetime. In children with two pathogenic FAH variants, GeneReviews states that early diagnosis with nitisinone and a low-tyrosine diet “has resulted in a greater than 90% survival rate”. When nitisinone starts in infancy, it reports liver cancer risk in those children as “extremely low, estimated at around 5% or less”.

A 15-year study across 77 sites in 17 European countries followed 315 patients with two pathogenic FAH variants, with 3,172.7 patient-years of drug exposure. Its headline finding was stark. Liver transplant or death happened in none of the 70 affected infants who started treatment before 28 days of age. Among the 268 affected patients who started later, 35, or 13%, had one of those outcomes.

A systematic review pointed the same way. It reported 0% transplantation among affected children treated earlier, against 25% to 60% among affected children treated later. Its authors rated study quality as moderate to weak, with a high risk of confounding.

The honest limits belong here too. One study compared 19 treated patients with two pathogenic FAH variants against 19 matched healthy controls. It found lower estimated IQ, weaker working memory and mental flexibility, and weaker social thinking in the treated group. That group was small and mixed, so the authors treat it as a question to keep studying rather than a reason to doubt treatment.

Monitoring practice also still varies between expert centres. That is why two separate 2025 European papers appeared: a MetabERN practice overview and consensus recommendations from the German-speaking countries. Both are European documents and do not set US or Canadian practice. Families living with this disease work with a metabolic specialist, not with an article.

Section recap: The FDA approved nitisinone on 2002-01-18, and Health Canada issued a Notice of Compliance for Orfadin on 2016-12-13 after supplying it since 1994. With early treatment, survival in affected children tops 90%, and their liver cancer risk is around 5% or less.

Telling the family and protecting the paperwork: cascade testing, options, GINA and Canada’s GNDA

A carrier result is information that travels through a family, and it raises a legal question that deserves an exact answer. Two laws frame that answer: the US Genetic Information Nondiscrimination Act (GINA) and Canada’s Genetic Non-Discrimination Act (GNDA).

Cascade testing is the efficient way to share it. At least one parent of a carrier also carries the variant, and each full sibling has about a 50% chance. Relatives can then be offered a targeted test for the known family variant. That single-variant test is faster and cheaper than a full panel, because the lab already knows exactly what to look for.

A short, low-drama message works better than a long one. Name the gene, say that carriers are healthy, and explain that two partners must carry variants in the same gene.

If both partners test positive for pathogenic FAH variants, the options are a menu rather than a ranking, and none of them is recommended here.

• Natural conception, with newborn screening as the safety net
• Prenatal diagnosis during a pregnancy
• IVF with preimplantation genetic testing for monogenic disease (PGT-M)
• Donor eggs or donor sperm
• Adoption

Funding differs sharply. PGT-M is generally self-pay in the United States, and funded unevenly across Canadian provinces. GeneReviews supports talking these options through with young adults who are carriers or at risk of being carriers, ideally with a certified counselor.

The legal picture differs by country and by product line. In the United States, GINA, passed in 2008, limits how health insurers use genetic information under Title I. Title II bars employers from using genetic information in hiring and other job decisions.

The gaps matter most here. GINA does not cover life, disability, or long-term care insurance, and only some state laws add cover. It also does not apply to employers with fewer than 15 staff, and it does not stop an insurer from weighing a disease that has actually shown up.

Canada drafted its law differently. The GNDA, S.C. 2017, c. 3, was assented to on 2017-05-04. It bars anyone from requiring a person to take a genetic test, or to hand over the results, as a condition of providing goods or services. The same bar covers entering, continuing, or setting the terms of a contract, with exceptions for health care practitioners and researchers.

The Act also amended the Canada Labour Code, and added genetic characteristics as a prohibited ground of discrimination under the Canadian Human Rights Act. The Supreme Court of Canada upheld it in Reference re Genetic Non-Discrimination Act, 2020 SCC 17, a 5-4 judgment released on 2020-07-10. Unlike GINA, the Canadian law is written around goods, services, and contracts in general, rather than carved out by insurance product line.

Laws and practice are not the same thing. A 2024 comparative review in FACETS looked at Canadian life insurance application forms before and after the Act, and reported little practical change. So read the forms closely, and ask an insurance broker about a given policy. Do not assume either full cover or none.

One last step. Home DNA firms change owners and rewrite their terms. So it is worth checking the current data-deletion and data-sharing settings in an account. Then make the appointment: an ABGC-certified counselor through the NSGC directory in the United States, or a CAGC-certified counselor or provincial genetics clinic in Canada, ideally before conception.

Section recap: Targeted single-variant testing is the efficient route for relatives, and GINA covers US health insurance and employment but not life, disability, or long-term care insurance. Canada’s GNDA was upheld 5-4 on 2020-07-10, though a 2024 review of insurer forms found little practical change.

Frequently asked questions

Will I get tyrosinemia type I because I am a carrier?

No. GeneReviews states that heterozygotes are asymptomatic and are not at risk of developing the disorder. One working FAH copy still makes working enzyme, so succinylacetone does not build up. The liver-failure, cancer, and transplant numbers in the research describe people with two pathogenic FAH variants. If a specific result is unclear, a doctor or certified genetic counselor can confirm what it means.

Will my children inherit it?

If only one birth parent carries a pathogenic FAH variant, no child of that couple can have the condition. Each child has about a 50% chance of being a healthy carrier instead. If both parents carry pathogenic FAH variants, GeneReviews gives each pregnancy a 25% chance of an affected child. The other outcomes are a 50% chance of a healthy carrier and a 25% chance of neither. That is why testing the partner is the decisive next step.

Will this affect my health, life, or disability insurance?

In the United States, GINA limits the use of genetic information in health insurance and employment, but it does not cover life, disability, or long-term care insurance. Some states add cover in those lines. In Canada, the Genetic Non-Discrimination Act bars anyone from requiring a genetic test or its disclosure as a condition of a contract or service. The Supreme Court upheld it 5-4 on 2020-07-10. A 2024 review of Canadian life insurance forms still found little practical change.

Can my employer find out?

In the United States, GINA Title II bars employers from using genetic information in job decisions, and limits how they may acquire or share it. It does not apply to employers with fewer than 15 staff. In Canada, the Genetic Non-Discrimination Act amended the Canada Labour Code, so staff cannot be made to take or disclose a genetic test. It also added genetic characteristics to the Canadian Human Rights Act. Workplace questions belong with an employment lawyer.

Should I get a second opinion or a confirming test?

A home carrier report is a screen, not a diagnosis, and the company’s own text says such reports cannot determine whether a person has two copies of a variant. The standard next step is a repeat test in a CLIA-certified US lab, or an accredited Canadian clinical lab. Full FAH sequencing plus deletion and duplication analysis is used where needed. A genetics referral is the usual way to arrange it.

Summary

An FAH carrier result answers a narrower question than it looks like it does. It says that one copy of one gene carries a pathogenic variant. GeneReviews is clear that such carriers have no symptoms and are not at risk of the disorder. The severe picture attached to this disease in search results belongs to children with two pathogenic variants. It is also no longer the picture it once was. GeneReviews reports survival above 90% in those children with early diagnosis, nitisinone, and diet, plus liver cancer risk around 5% or less when treatment starts in infancy.

Ancestry sets a starting point rather than an answer. Roughly 1 in 100,000 worldwide from MedlinePlus, about 1 in 16,000 across Quebec, and 1 in 1,846 births in Saguenay-Lac-Saint-Jean are all real numbers describing different groups. A negative four-variant home screen in a partner lowers what risk is left without erasing it, because a targeted panel cannot see past its own list.

Three concrete actions follow. Confirm the result through a clinical lab. Arrange clinic-grade FAH testing for the reproductive partner, since that is the test that changes the math. Book a certified genetic counselor before a pregnancy rather than during one, through the NSGC directory in the US or a provincial genetics program in Canada.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Sniderman King L, Trahms C, Scott CR (updated by Chinsky JM et al.). Tyrosinemia Type I. GeneReviews, University of Washington / NCBI Bookshelf NBK1515 (initial posting 2006-07-24; last update 2025-11-20). https://www.ncbi.nlm.nih.gov/books/NBK1515/
2. MedlinePlus Genetics, US National Library of Medicine (NIH). Tyrosinemia (condition summary). https://medlineplus.gov/genetics/condition/tyrosinemia/
3. MedlinePlus Genetics, US National Library of Medicine (NIH). FAH gene (fumarylacetoacetate hydrolase). https://medlineplus.gov/genetics/gene/fah/
4. US Food and Drug Administration, Drugs@FDA. ORFADIN (nitisinone) capsules, NDA 021232 — approval history (original approval action date 2002-01-18; priority review; orphan). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021232
5. Health Canada, Drug and Health Product Portal. Summary Basis of Decision for Orfadin (nitisinone), New Drug Submission control number 193226 (SBD00344). https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00344
6. Health Canada, Drug Product Database (public API). Records for the active ingredient nitisinone in Canada. https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=nitisinone&type=json
7. Chinsky JM, Singh R, Ficicioglu C, van Karnebeek CDM, Grompe M, Mitchell G, Waisbren SE, Gucsavas-Calikoglu M, Wasserstein MP, Coakley K, Scott CR (2017). Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genetics in Medicine 19(12). PMID 28771246; PMC5729346; DOI 10.1038/gim.2017.101. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729346/
8. Spiekerkoetter U, Couce ML, Das AM, et al. (2021). Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study. The Lancet Diabetes & Endocrinology 9(7):427-435. PMID 34023005; DOI 10.1016/S2213-8587(21)00092-9. https://pubmed.ncbi.nlm.nih.gov/34023005/
9. Stinton C, Geppert J, Freeman K, Clarke A, Johnson S, Fraser H, Sutcliffe P, Taylor-Phillips S (2017). Newborn screening for Tyrosinemia type 1 using succinylacetone — a systematic review of test accuracy. Orphanet Journal of Rare Diseases 12(1):48. PMID 28274233; PMC5343414; DOI 10.1186/s13023-017-0599-z. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343414/
10. Geppert J, Stinton C, Freeman K, Fraser H, Clarke A, Johnson S, Sutcliffe P, Taylor-Phillips S (2017). Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review. Orphanet Journal of Rare Diseases 12(1):154. PMID 28893311; PMC5594482; DOI 10.1186/s13023-017-0696-z. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594482/
11. Dijkstra AM, Evers-van Vliet K, Heiner-Fokkema MR, Bodewes FAJA, Bos DK, Zsiros J, van Aerde KJ, Koop K, van Spronsen FJ, Lubout CMA (2023). A False-Negative Newborn Screen for Tyrosinemia Type 1 — Need for Re-Evaluation of Newborn Screening with Succinylacetone. International Journal of Neonatal Screening 9(4):66. PMID 38132825; PMC10744279; DOI 10.3390/ijns9040066. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10744279/
12. Grompe M, St-Louis M, Demers SI, al-Dhalimy M, Leclerc B, Tanguay RM (1994). A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. New England Journal of Medicine 331(6):353-357. PMID 8028615; DOI 10.1056/NEJM199408113310603. https://pubmed.ncbi.nlm.nih.gov/8028615/
13. van Ginkel WG, Jahja R, Huijbregts SCJ, et al. (2016). Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls. Orphanet Journal of Rare Diseases 11(1):87. PMID 27356512; DOI 10.1186/s13023-016-0472-5. https://pubmed.ncbi.nlm.nih.gov/27356512/
14. Gregg AR, Aarabi M, Klugman S, et al.; ACMG Professional Practice and Guidelines Committee (2021). Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics. Genetics in Medicine 23(10):1793-1806 (correction 23(10):2015). PMID 34285390; PMC8488021; DOI 10.1038/s41436-021-01203-z. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488021/
15. Kuypers AM, Das AM, Maiorana A, Heiner-Fokkema MR, van Spronsen FJ; TT1 MetabERN Professional Collaboration Group (2025). Overview of European Practices for Management of Tyrosinemia Type 1: Towards European Guidelines. Journal of Inherited Metabolic Disease 48(5):e70089. PMID 40965374; PMC12445258; DOI 10.1002/jimd.70089. https://pubmed.ncbi.nlm.nih.gov/40965374/
16. Consensus group of the German-speaking countries (2025). Diagnosis, treatment, management and monitoring of patients with tyrosinaemia type 1: consensus group recommendations from the German-speaking countries. Journal of Inherited Metabolic Disease 48(1) (first published online 2024-12-15). DOI 10.1002/jimd.12824. https://doi.org/10.1002/jimd.12824
17. Department of Justice Canada, Justice Laws Website. Genetic Non-Discrimination Act, S.C. 2017, c. 3 (assented to 2017-05-04). https://laws-lois.justice.gc.ca/eng/annualstatutes/2017_3/page-1.html
18. Supreme Court of Canada. Reference re Genetic Non-Discrimination Act, 2020 SCC 17, [2020] 2 SCR 283 (judgment 2020-07-10). https://decisions.scc-csc.ca/scc-csc/scc-csc/en/item/18417/index.do
19. US Equal Employment Opportunity Commission. Genetic Information Nondiscrimination Act of 2008 (Pub. L. 110-233): https://www.eeoc.gov/statutes/genetic-information-nondiscrimination-act-2008 — with National Human Genome Research Institute (NIH) genetic discrimination overview: https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
20. Fernando K, Kondrup E, Cheung K, Uberoi D, Joly Y (2024). Still using genetic data? A comparative review of Canadian life insurance application forms before and after the GNDA. FACETS 9. DOI 10.1139/facets-2023-0101. https://doi.org/10.1139/facets-2023-0101
21. Health Resources and Services Administration, Advisory Committee on Heritable Disorders in Newborns and Children. Recommended Uniform Screening Panel (RUSP) core conditions. https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp
22. 23andMe, Inc. Tyrosinemia Type I: Genetics and More — Carrier Status report topic page (company product documentation). https://www.23andme.com/en-ca/topics/carrier/tyrosinemia-type-i/
23. National Society of Genetic Counselors, Find a Genetic Counselor directory: https://www.findageneticcounselor.com/ — American Board of Genetic Counseling: https://www.abgc.net/ — Canadian Association of Genetic Counsellors: https://www.cagc-accg.ca/
24. NIH National Center for Biotechnology Information, Genetic Testing Registry. Tyrosinemia type I (concept C0268490) — registered clinical tests. https://www.ncbi.nlm.nih.gov/gtr/conditions/C0268490/

Last updated: 2026-08-23

Author: genelumen editorial team. This article aggregates 24 sources from peer-reviewed medical literature and public health agencies (tier 1=13 / tier 2=10 / tier 4=1), including NIH resources (MedlinePlus Genetics, the Genetic Testing Registry, NHGRI), GeneReviews, the FDA, Health Canada, ACMG guidelines, Canadian federal statute and Supreme Court sources, and PubMed-indexed publications. Editorial responsibility: Yu Mizuno, a non-physician research editor.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911.

Related: Metabolic and Hematologic Genetic Diseases category

🌐 日本語版: https://genelumen.com/ja/ja-metabolic-hematologic-genetic/tyrosinemia-type1-fah-carrier-inheritance-japan